ACRP-CP Dumps ACRP-CP Braindumps

ACRP-CP Real Questions ACRP-CP Practice Test ACRP-CP Actual Questions


killexams.com


Nursing


ACRP-CP


Certified Clinical Research Professional - Certified Professional


https://killexams.com/pass4sure/exam-detail/ACRP-CP

Question: 1


Which of the following is an example of a double-blind study design?


  1. Investigators are unaware of the treatment assignments, but participants are aware.


    articipants and investigators are aware of the treatment assignments. articipants and investigators are unaware of the treatment assignments


    wer: D


    anation: In a double-blind study design, both the participants and the stigators are unaware of the treatment assignments. This design helps mize biases and ensures the objectivity of the study outcomes. Blindin cularly important when evaluating interventions to avoid any potential ence or bias due to the participants' or investigators' knowledge of the ment assignments.


    stion: 2


    ch of the following is an example of an electronic data capture (EDC) m used in clinical trials?


    racle Clinical

  2. Participants are unaware of the treatment assignments, but investigators are aware.

  3. P

  4. P .

Ans Expl

inve

mini g is

parti influ treat


Que


Whi syste


  1. O

  2. Paper case report forms (CRFs)

  3. Microsoft Excel

  4. Adobe Acrobat


Answer: A

Explanation: Oracle Clinical is an example of an electronic data capture (EDC) system commonly used in clinical trials. EDC systems are software applications designed to collect, manage, and store clinical trial data electronically. These systems streamline data collection and facilitate data cleaning, analysis, and reporting. Unlike paper case report forms (CRFs) or general-purpose software like Microsoft Excel or Adobe Acrobat, specialized EDC systems offer robust features and data validation capabilitiesQuestion 8:


ch of the following actions is NOT considered a part of study and site agement in clinical research?


nsuring adequate training of site staff onitoring study progress and data quality

anaging participant recruitment and enrollment onducting statistical analysis of study results


wer: D


anation: Conducting statistical analysis of study results is not typicall idered a part of study and site management in clinical research. Study anagement involve activities such as ensuring adequate training of si

monitoring study progress and data quality, managing participant itment and enrollment, and overseeing compliance with the study pro stical analysis of study results is usually performed by biostatisticians nalysts.

Whi man


  1. E

  2. M

  3. M

  4. C


Ans


Expl y

cons and

site m te

staff,

recru tocol.

Stati or

data a


Question: 3


Which of the following is a key principle of Good Clinical Practice (GCP)?


  1. Maximizing sponsor's financial interests

  2. Protecting the rights and well-being of study participants

  3. Minimizing the use of informed consent

  4. Concealing potential risks from study participants Answer: B

ent, minimizing risks to participants, and maintaining confidentiality o cipants' personal information.


stion: 4


ch regulatory authority is responsible for the approval of investigation rugs (INDs) in the United States?


uropean Medicines Agency (EMA)

harmaceuticals and Medical Devices Agency (PMDA) ood and Drug Administration (FDA)

ealth Canada wer: C

anation: The Food and Drug Administration (FDA) is the regulatory ority responsible for the approval of investigational new drugs (INDs) nited States. The FDA plays a crucial role in ensuring the safety and

Explanation: A key principle of Good Clinical Practice (GCP) is protecting the rights and well-being of study participants. GCP guidelines are designed to ensure that clinical trials are conducted ethically and that the rights, safety, and well-being of trial participants are protected. This includes obtaining informed cons f

parti


Que


Whi al

new d


  1. E

  2. P

  3. F

  4. H

Ans Expl

auth in

the U

efficacy of drugs and biologics before they can be marketed for general use. The FDA reviews the data provided by sponsors during the IND application process to determine whether the investigational product can proceed to clinical trials.


Question: 5

Which of the following is NOT a responsibility of a clinical research coordinator (CRC) during a clinical trial?


  1. Ensuring compliance with the protocol

  2. Analyzing and interpreting study data

  3. Obtaining informed consent from study participants

  4. Documenting and reporting adverse events



wer: B


anation: Analyzing and interpreting study data is not typically a onsibility of a clinical research coordinator (CRC) during a clinical tri

RC's primary role is to ensure compliance with the study protocol, ding participant recruitment, data collection, and documentation. yzing and interpreting study data is often performed by the study spo

anagement personnel, biostatisticians, or other specialized roles.


stion: 6


ch of the following is an example of a serious adverse event (SAE) in cal trial?


ild headache emporary skin rash yocardial infarction

Ans Expl

resp al.

The C inclu

Anal nsor,

data m


Que


Whi a

clini


  1. M

  2. T

  3. M

  4. Transient nausea Answer: C

Explanation: An SAE in a clinical trial refers to any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent

or significant disability/incapacity, or causes a congenital anomaly/birth defect. Among the options, myocardial infarction (heart attack) is a severe and potentially life-threatening event that qualifies as a serious adverse event.


Question: 7



ase-control study ross-sectional study ohort study

andomized controlled trial wer: D

anation: The most appropriate study design for evaluating the effectiv ew drug compared to an existing standard of care is a randomized olled trial (RCT). RCTs are considered the gold standard for assessin acy and safety of interventions. In an RCT, participants are randomly ned to receive either the new drug or the standard of care, allowing fo

comparison between the two groups.


stion: 8


ch of the following medications require close monitoring of digoxin le

Which of the following study designs is most appropriate for evaluating the effectiveness of a new drug compared to an existing standard of care?


  1. C

  2. C

  3. C

  4. R


Ans


Expl eness

of a n

contr g the

effic

assig r a

direct


Que


Whi vels

when started?


  1. Loratadine

  2. Diphenhydramine

  3. Albuterol

  4. Ipratropium

Answer: C


when initiating Albuterol therapy to ensure patient safety.

Explanation: Digoxin levels need to be monitored closely when starting Albuterol. Albuterol, a bronchodilator commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD), can cause an increase in serum digoxin levels. This interaction could lead to digoxin toxicity, which can manifest as symptoms such as nausea, vomiting, visual disturbances, and cardiac arrhythmias. Therefore, it is important to closely monitor digoxin levels